Journal article
High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival
KK Brieger, MT Phung, B Mukherjee, KM Bakulski, H Anton-Culver, EV Bandera, DDL Bowtell, DW Cramer, A DeFazio, JA Doherty, S Fereday, RT Fortner, A Gentry-Maharaj, EL Goode, MT Goodman, HR Harris, K Matsuo, U Menon, F Modugno, KB Moysich Show all
Cancer Epidemiology Biomarkers and Prevention | Published : 2022
Abstract
Background: There is suggestive evidence that inflammation is (IRRS) was developed, and its association with survival was related to ovarian cancer survival. However, more research is assessed using Cox proportional hazards models in the remaining needed to identify inflammation-related factors that are associated 50% of the data. with ovarian cancer survival and to determine their combined Results: There was a statistically significant trend of increasing effects. risk of death per quartile of the IRRS [HR ¼ 1.09; 95% confidence Methods: This analysis used pooled data on 8,147 women with interval (CI), 1.03–1.14]. Women in the upper quartile of the IRRS invasive epithelial ovarian cancer fr..
View full abstractRelated Projects (6)
Grants
Awarded by Mayo Foundation for Medical Education and Research
Funding Acknowledgements
The OCAC is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07 to A. Berchuck) . The scientific development and funding for this project were in part supported by the U.S. NCI GAME-ON Post-GWAS Initiative (U19-CA148112 to C.L. Pearce and J.M. Schildkraut) . Funding for individual studies: AUS: The Australian Ovarian Cancer Study (AOCS) was supported by the U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729 to D.D.L. Bowtell and P.M. Webb) ; National Health & Medical Research Council of Australia (199600, 400413 and 400281 to D.D.L. Bowtell and P.M. Webb) ; Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia (Multi-State Applications 191, 211 and 182 to D.D.L. Bowtell and P.M. Webb) . AOCS gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation; D.D.L. Bowtell is supported by the National Health and Medical Research Council of Australia (NHMRC; APP1117044, APP1161198, APP1092856) ; P.M. Webb is supported by NHMRC Investigator Grant APP1173346; CON: NIH (R01-CA063678, R01-CA074850, and R01-CA080742 to H.A. Risch) ; DOV: NIH (R01-CA112523 and R01-CA87538 to J.A. Doherty) ; HAW: U.S. NIH (R01-CA58598, N01-CN-55424 and N01-PC-67001 to M.T. Goodman) ; HOP: University of Pittsburgh School of Medicine Dean's Faculty Advancement Award (to F. Modugno) , Department of Defense (DAMD17-02-1-0669 to F. Modugno) , and NCI (K07-CA080668 to F. Modugno; P50-CA159981 and R01-CA126841 to K.B. Moysich; R01-CA95023 and MO1-RR000056 to F. Modugno and K.B. Moysich) ; MAY: NIH (R01-CA122443, P30-CA15083, and P50-CA136393 to E.L. Goode) ; Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation (to E.L. Goode) ; NCO: National Institutes of Health (R01-CA76016 to A. Berchuck and J.M. Schildkraut) and the Department of Defense (DAMD17-02-1-0666 to A. Berchuck) ; NEC: NIH (R01-CA54419 and P50-CA105009 to D.W. Cramer) and Department of Defense (W81XWH-10-1-02802 to K.L. Terry) ; NJO: NCI (NIH-K07 CA095666, R01-CA83918, NIH-K22-CA138563, and P30-CA072720 to E.V. Bandera) and the Cancer Institute of New Jersey (to E.V. Bandera) ; UCI: NIH (R01-CA058860 to H. Anton-Culver) and the Lon V Smith Foundation (grant LVS-39420 to H. Anton-Culver) ; USC: NIH (P01CA17054, N01PC67010, N01CN025403 to A.H. Wu, M.C. Pike, and C.L. Pearce; P30CA14089 to A.H. Wu and M.C. Pike; R01CA61132 to M.C. Pike; R03CA113148 and R03CA115195 to C.L. Pearce) ; and California Cancer Research Program (00-01389V-20170 to M.C. Pike and C.L. Pearce; 2II0200 to A.H. Wu) ; M.C. Pike is partially supported by the NIH/NCI Support Grant P30 CA008748 to Memorial Sloan Kettering Cancer Center. We are grateful to the family and friends of Kathryn Sladek Smith for their generous support of the OCAC through their donations to the Ovarian Cancer Research Fund. We thank the study participants, doctors, nurses, clinical and scientific collaborators, health care providers, and health information sources who have contributed to the many studies contributing to this manu-script. Acknowledgements for individual studies: AUS: The AOCS also acknowl-edges the cooperation of the participating institutions in Australia, and the contribution of the study nurses, research assistants, and all clinical and scientific collaborators. The complete AOCS Study Group can be found at www.aocstudy. org. We would like to thank all of the women who participated in this research program; CON: The cooperation of the 32 Connecticut hospitals, including Stamford Hospital, in allowing patient access, is gratefully acknowledged. This study was approved by the State of Connecticut Department of Public Health Human Investigation Committee. Certain data used in this study were obtained from the Connecticut Tumor Registry in the Connecticut Department of Public Health. The authors assume full responsibility for analyses and interpretation of these data; NJO: Drs. Sara Olson, Lisa Paddock, and Lorna Rodriguez, and research staff at the Rutgers Cancer Institute of New Jersey, Memorial Sloan-Kettering Cancer Center, and the New Jersey State Cancer Registry.